Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.47 |
| ▸ | TXN | P10599 | 1/20 | 0.42 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | ADK | P55263 | 1/20 | 0.39 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL229404 | 0.82 | HDAC1 (0.53) | TAAR1GRIN2BHSD17B10GRIN2AHDAC1 | |
| Hydrochloric Acid SCHEMBL5155818 | 0.81 | HDAC1 (0.52) | TAAR1GRIN2BHSD17B10GRIN2AHDAC1 | |
| SCHEMBL3503342 | 0.72 | TXN (0.55) | TAAR1TXNTXNRD1GRIN2BMTOR | |
| SCHEMBL29230334 | 0.72 | HSD17B10 (0.64) | HSD17B10CYP2D6TSHRSMN1; SMN2CYP1A2 | |
| SCHEMBL22341497 | 0.72 | — | — | |
| SCHEMBL7064359 | 0.72 | — | — | |
| SCHEMBL537743 | 0.69 | EHMT2 (0.59) | HSD17B10HDAC1CYP2D6SMN1; SMN2CYP1A2 | |
| SCHEMBL31202896 | 0.69 | TXN (0.54) | TAAR1TXNTXNRD1GRIN2BCYP2D6 | |
| SCHEMBL5032699 | 0.68 | MTOR (0.45) | TAAR1TXNTXNRD1GRIN2BGRIN2A | |
| SCHEMBL2812932 | 0.68 | TXN (0.45) | TAAR1TXNTXNRD1SMN1; SMN2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009082686-A1 | COMPOSITIONS AND METHODS FOR USING ASYMMETRIC DISULFIDES | PROLX PHARMACEUTICALS CORP. (US) | 2009-07-02 | — | — | WO | disclosed |
| EP-1786477-A2 | METHOD OF PRESELECTION PATIENTS FOR ANTI-VEGF, ANTI-HIF-1 OR ANTI-THIOREDOXIN THERAPY | Prolx Pharmaceuticals Corp. (US) | 2007-05-23 | — | — | EP | disclosed |
| US-20060148674-A1 | Therapeutic composition | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2006-07-06 | — | — | US | disclosed |
| WO-2006072113-A2 | THERAPEUTIC COMPOSITION | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2006-07-06 | — | — | WO | disclosed |
| US-20060104902-A1 | Method of preselection patients for anti-VEGF, anti-HIF-1 or anti-thioredoxin therapy | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-05-18 | — | — | US | disclosed |
| WO-2006023658-A2 | METHOD OF PRE-SELECTING PATIENTS FOR ANTI-VEGF, ANTI-HIF-1 OR ANTI-THIOREDOXIN THERAPY | PROLX PHARMACEUTICALS CORP. (US) | 2006-03-02 | — | — | WO | disclosed |
| US-20030176512-A1 | Asymmetric disulfides and methods of using same | PROLX PHARMACEUTICALS CORPORATION (CA) | 2003-09-18 | — | — | US | disclosed |
| US-6552060-B1 | Inhibits abnormal cellular proliferation and restores or prevents inhibition of cellular apoptosis | PROLX PHARMACEUTICALS, INC. | 2003-04-22 | — | — | US | disclosed |
| US-6372772-B1 | ENZYME INHIBITORS FOR REDUCTASE SYSTEMS IN CELLS | PROLX PHARMACEUTICALS CORPORATION | 2002-04-16 | — | — | US | disclosed |
| WO-2000006088-A2 | INHIBITORS OF REDOX SIGNALING AND METHODS OF USING SAME | PROLX PHARMACEUTICALS, LP (US) | 2000-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060104902-A1 | Method of preselection patients for anti-VEGF, anti-HIF-1 or anti-thioredoxin therapy | HIF1A, TXNRD3, HIF1AN | TAAR1 2734/4885TXN 6/4885TXNRD1 5/4885 |
| US-20030176512-A1 | Asymmetric disulfides and methods of using same | PRDX3, PDIA5, PRDX5 | TAAR1 4857/4885TXN 11/4885TXNRD1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.